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INTRODUCTION
The 29th Annual Stoneburner Lecture Series
was sponsored this year by the Department of
Neurology because we sensed a need and a desire for
a symposium approaching common neurologic problems encountered by primary care physicians. The
attendance at the series was gratifying to the partici pating lecturers and confirmed our view .
Our approach to each topic has been to dwell on
recognition and diagnosis, and to discuss new therapy
and therapeutic dilemmas, omitting or touching only
briefly on such areas as basic anatomy , physiology,
chemistry, and pathology. In this first part of a twopart issue, I discuss some of the problems of treating
Parkinson ' s disease that somehow have not been
solved by the highly touted levodopa, Dr. Harbison
provides us with an overview of sometimes vexing
problems that present as episodic visual loss, and Dr.
Grindal provides us with a rational approach to dizzy
patients. Our Stoneburner Lecturer, Dr. Clark Millikan, offers an in-depth review of cerebrovascular
insufficiency. Finally, Dr. Calabrese covers the value
of the cerebrospinal fluid examination and certain
measures that may be taken to improve interpretation.
In organizing this symposium, we have attempted to provide the primary care physician with
some insight, perhaps new, into these complex and
common areas, but it is necessary for primary care
physicians themselves to continue providing us with
information about their problem areas .
JOHN R . TAYLOR, M.D .

Assistant Professor
Department of Neurology
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Current Management of Parkinson ism
JOHN R. TAYLOR, M .D .

Assistant Professor, Department of Neurology, Medical College of Virginia, H ea/th Sciences Division of Virginia
Commonwealth University, Richmond, Virginia

James Parkinson, a London general practitioner
and political activist, 1 delivered his essay on the shaking palsy in 1817 and encouraged others who "humanely employ anatomical examination " to study
the cause and nature of "this malady." Even in his
wildest fantasies I seriously doubt that he dreamed of
the extent to which his advice would be followed .
Today, in spite of a recog.nized incidence of only 20
cases per 100,000 persons per year,2 articles concerning this disorder appear in nearly every issue of
many neurology journals. The reason for this interest
is explained by the significant work that took place in
the 1960's. During that period a series of biochemical
steps leading from tyrosine to biogenically active
amines was elucidated, 3 and, further, the action of
these amines at brain synapses was convincingly hypothesized.4 Tyrosine is converted to levodopa and
then to dopamine, a neurotransmitter. Since dopamine parenterally does not enter the brain , it was
found that large doses of its precursor, levodopa,
resulted in some levod opa entering the brain, driving
the reaction in favor of more dopamine, and therefore enhancing neurotransmission. It is this concept
that has excited neurologists out of all proportion to
the frequency of Parkinson's disease in the genera l
population. As is now known , the pathology of Parkinson's disease lies in the substantia nigra, 5 where
neurons that ordinarily project to the striatum 6 and
transmit via dopamine are degenerating; hence the
rationale for the use of levodopa as a therapeutic
tool. As attractive as this model is, I remain suspicious that the mechanisms are far more complex
than as yet determined.
Correspondence and reprint requests to: Dr. John R. Taylor,
Department of Neurology , Box 698 . Medical College of Virginia ,
Richmond, Virginia 23298.
MCV QUARTERLY 12(3): 93-98 , 1976

In the management of Parkinson's disease, one
must be reasonably certain of the diagnosis. In spite
of the foregoing sophisticated biochemistry , there is
really no laboratory test for the disease, so it becomes
an entity that must be recognized on purely clinical
grounds. While the differential diagnosis can be quite
extensive and includes such rare entities as manganese poisoning, as well as such usually apparent
causes as phenothiazine intoxication or carbon monoxide sequelae, several disorders and etio logies account for most of our diagnostic problems . Although
we think of Parkinsonism as a triad of rest tremor,
rigidity , and akinesia, the onset may be with any one
of these, and if it is with tremor, the distinction from
essential tremor may be difficult. Essential tremor,
sometimes inherited as an autosomal dominant, is
occasiona ll y seen and resembles Parkinson's disease.
The tremor is a little faster 7 and while many authors
state that it begins in an arm, as does Parkinsonism,
the head often begins to titubate soon after the
tremor begins in the hand. The onset of essential (or
familial) tremor is usually earlier than in Parkinson ' s
disease, and may even be in childhood. Its progression is slow , and it often stabi li zes so that the physician may encounter a patient who recounts years of
tremor, often misdiagnosed as nervousness or Parkinsonism . The rigidity and akinesia of the latter are
never present in essential tremor. Patients with essential tremor usually display more tremor on intention
than at rest, and often find that a moderate amount
of alcohol relieves their tremor for a time. The combination of family history , long-standing symptoms,
head titubation, and absence of either rigidity or
akinesia will almost a lways estab li sh the diagnosis of
essential tremor. Levodopa is of no value .
Cerebell ar tremor associated with cerebellar
degeneration or other cerebellar diseases is an occa-
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sional problem. Usually the absence of rest tremor,
akinesia, and rigidity, plus other signs, for example,
truncal ataxia, will allow an easy distinction.
A variety of degenerative diseases may present
with poverty of motion and a degree of rigidity. Most
of the presenile dementias can present in this fashion,
but the predominance of the dementing element usually permits an easy differential diagnosis to be made .
Certain rare entities have been a problem, however,
one of which is progressive supranuclear palsy.8
Patients with this disease display many Parkinsonian
features, including, occasionally , involuntary movements; however, early loss of voluntary vertical gaze,
especially down gaze (with spared reflex gaze mechanisms, for example, oculovestibular reflexes) associated with conspicuous rigidity , along with a fairly
rapid course, are usually enough to permit most clinicians to arrive at the diagnosis. Levodopa is of limited, if any, benefit.
Shy-Drager syndrome (idiopathic orthostatic
hypotension )9 is another rare syndrome that has led
to some diagnostic difficulty, though usually easily
resolved . This disease reflects, to some extent, a continuum of Parkinsonism; however, the Shy-Drager
syndrome evinces a much more profound involvement of autonomic nuclei , with consequent severe orthostatic hypotension, anhidrosis, and incontinence, to the degree that the usually present
bradykinesia , rigidity, and occasional tremor are
overshadowed. Nevertheless, since orthostatic hypotension is occasionally a feature of Parkinsonism, the
distinction is sometimes a problem. Patients with
Shy-Drager syndrome respond poorly to levodopa .
A part from these syndromes, the differential
diagnosis of Parkinson's disease revolves mainly
around its etiology. Though some reputable investigators appear to feel that the encephalitis epidemic in the second and third decades of this century
accounts for most of the Parkinsonism we see, I
believe that there are multiple etiologies for the disease just as there are for hemiplegia , and that the duty
of physicians encountering patients with Parkinsonism is to attempt to elucidate the etiology.
Another area of interest that should be mentioned is genetic Parkinson's disease. 10 There is abundant evidence that familial clustering occurs in
Parkinsonism, and the finding that individuals
predisposed to developing Parkinsonian symptoms,
after treatment with phenothiazines, have a higher
incidence of family members with spontaneous Park-

inson's disease" adds further weight to the idea that
some Parkinsonism is hereditary , perhaps an inherited tyrosine hydroxylase deficiency . Nevertheless,
this is not sufficiently established to require genetic counseling, nor is hereditary Parkinsonism sufficiently different from other forms to necessitate differences in therapy . Furthermore, familial clustering
alone is insufficient evidence to rule out an infectious
etiology .
Therapeutic avenues open to the physician managing patients with Parkinson's disease can best be
summarized by considering the past, present, and
future. That the treatment of this complex disease
should change over the years is not surprising; however, that the treatment should take such profound
swings over a period of fifteen years is surprising.
The Past. Charcot is said to have noted the value
of atropine over 100 years ago. 12 Since then , and until
levodopa appeared on the scene, atropine and about
seven or eight similar drugs were the medications of
choice in Parkinson's disease . The differences in these
drugs are not great, 13 and all share, to a variable
degree, anticholinergic side effects. The peripheral
side effects of these drugs are well known; however,
centrally, drug intoxication may lead to ataxia, dysarthria, hyperthermia, and frank psychosis. The
drugs must be introduced in low dosages and in creased slowly until improvement occurs or side effects force a halt to further increment of dosage. A
modest improvement in rigidity and tremor can be
expected in 70% of patients; however, akinesia does
not respond to this treatment. 14 These drugs remain
valuable in the treatment of mild Parkinsonism and
as adjuncts to levodopa. Diphenhydramine (Benadryl@), an antihistamine, also possesses an atropine-like action, inhibiting striatal dopamine uptake,
and is only mildly less potent than benztropine (Cogentin@).
Amphetamines enjoyed some popularity in the
past. These drugs are chemically similar to dopamine
and seem to be beneficial. Their benefits , however,
are not great enough to override their side effects, and
they are no longer used to any extent. Surgery, involving destructive lesions in several areas of the
brain, but mostly in the thalamus, enjoyed a brief
popularity in the fifties and early sixties . Useful
mainly for tremor and least valuable in akinesia,
thalamotomy procedures were often impermanent in
their benefits and had occasional failures as well as
complications, such as hemiplegia. As a result, the
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use of thalamotomy waned rapidly after the development of levodopa, and the operation is now rarely
performed for Parkinson's disease.
The Present. Long in preparation, levodopa has
been in widespread experimental use for over seven
years, and in general use for over five years. 15 First
evaluations, particularly with patients early in the
course of their disease, indicated that 70% of patients
experienced at least a 50% improvement in their
symptoms, especially akinesia and rigidity. This is a
remarkable improvement for most patients. To
achieve this goal, the d?ily dosage must be slowly
worked up to levels of 5 to 9 gm, initiated at levels of
125 to 250 mg daily, with food. Single doses should
not exceed 1.5 to 2.0 gm 13 ; hence the need for multiple
doses. The frequency of side effects is extensive. In
one series of 100 patients, 16 49 developed abnormal
involuntary movements, 45 had gastrointestinal
problems, 30 had psychiatric manifestations, and 11
had symptomatic hypotension . Other side effects occurred less frequently. As a result of these side effects,
especially nausea, many patients never reach maximum dose levels, and treatment is discontinued because they cannot tolerate useful levels of the drug.
Part of this problem has been solved by combining
levodopa with carbidopa which is a chemical "lookalike" of levodopa that inhibits dopa-decarboxylase
extracerebrally. Thus, since 95% of levodopa is decarboxylated before it reaches the brain 17 (and is
therefore therapeutically ineffective), a combinat~on
drug allows levodopa to reach the brain in greater
amounts respective to the oral dose. The only combination currently available commercially is Sinemet
25/ 250® (Merck, Sharp, and Dohme). This product
provides a carbidopa: levodopa ratio of I : I 0, and
since carbidopa blocks at least 75% to 80% of peripheral decarboxylation of levodopa, it follows that a
Sinemet 25/250® is roughly equivalent to 1.0 gm of
oral levodopa, and in practice this seems to be the
case. In switching from levodopa to Sinemet 25/250®,
stop levodopa for 8 hours, then resume Sinemet 25/
250® at one-fourth the dose for levodopa. The only
real advantage to the com bi nation is the avoidance of
nausea, though a reduction in cardiac arrhythmias
and in hypotension has been reported . 17 According to
an oral communication from B. A. Huffman, in February 1976, the price of this combination drug is
15% to 20% above levodopa a lone and since its chief
value is in preventing nausea, the increased expense is
hardly justified for those who tolerate, one way or the
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other, this side effect. Nonetheless, this combination
drug offers a considerable advantage to those patients
who seem unable to overcome nausea at even low
doses. In addition, and of minor importance with
out-patients, one can advance the dosage faster with
combination therapy since nausea is a minimal problem. Finally, carbidopa inhibits the action of pyridoxine in reversing levodopa action; hence ordinary
multivitamins may be used when indicated.
Other side effects that deserve special mention
are the involuntary movements and the psychologic
problems. Both can take almost any form, both are
quite common complications, and, as a rule, the development of either problem is best managed by a
reduction in dose. Both are central effects of levodopa; hence they readily occur with either levodopa
alone or in combination with carbidopa.
A final note on side effects relates to orthostatic
hypotension. This is a well-recognized side effect, and
patients on levodopa should have periodic standing
blood pressure determinations. A reduction in levodopa dose is usually required if this side effect occurs.
Other drugs may also be used to advantage with
levodopa or levodopa/ca rbidopa. Atropine-like
agents have already been mentioned, and while they
were never shown to provide more than a 20% improvement in symptoms, this margin may occasionally be useful along with levodopa. Amantadine,
originally an antiviral drug, has more merit as an
adjunct as well as acting alone. In one study 18 involving 48 patients, benefits of 21 % to 39% occurred
in major Parkinsonian disa bilities. Side effects, consisting mainly of gastrointestinal disturbances, sleep
disturbances, and hallucinations occurred with
amantadine, but the frequency of these is low. The
dose used in this study was amantadine 200 mg daily
in divided doses. There is a tendency for benefits to
decline after several months.
Propranolol, a beta adrenergic blocking agent,
has also been used in a va riety of states with
tremor 19•20 and consequently we have tried it in combination with other drugs to relieve the tremor of
Parkinson's disease. The results have not been measured, but on occasion this has seemed to be a useful
drug. Other clinicians 21 have had similar experiences.
A maximum dose of 180 to 200 mg/ day must be
approached cautiously.
One may wonder why several drugs other than
levodopa have been mentioned. Several facets of the
nature of levodopa therapy account for this. First, a
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fairly large group of patients do not respond well to
it. Second, certain patients are unable to achieve adequa te levels due to side effects. And, finally, there
appears to be developin g a "resistance" to levodopa
benefit. 15 This resistance tak es several forms, but occurs in one way or another in the majority of pa ti ents.
In Barbeau's series, the percentage of patients with
excellent or good results initially was 79% and
dropped to 29% at 6 years, and 25% had stopped
levodopa. The predicted survival of severely akinetic
patients is 9.7 years, 22 thus it is suggested that
levodopa probably will not stop the progression of
Parkinsonism. Some investiga tors feel that there may
be a finite period of time in which levodopa is effective and therefore withold the drug until disability is
beginning to become clearly evident.
The resistance to treatment ta kes many forms,
but three mechani sms sta nd out:
I. End-of-dose ak in esia. Parkin sonian symptoms recur progressi vely earlier following a dose.
Levodopa levels are low, and more frequent spacing
of the drug is beneficial.
2. On / Off phenomenon . Patients note periods
in which there is a sudden return of Parkinsonian
sy mptom s, the " Off' ' period. The " On " period , unfortunately, is nearl y always complicated by dyskinesias , usually appendicular and fairly distressing. In
one report, 23 29 such patients were encountered in a
population of 300 Parkinson patients. Nineteen had
been on medication more than 24 months, suggesting
that the duration of the di sease or of levodopa therapy is of significance. The "Off'' period is characterized by low levodopa levels. This phenomenon is
poorly understood a nd its management a subject of
debate. Nevertheless, two views are worth mentioning. The first 24 embraces the concept that a hypersensitivity of the receptor occurs and suggests gradual
reduction in levodopa dose to levels of about onefifth the previous maintena nce dose. The second 25
invol ves a reduction in presumably competing a mino
acids in the diet by reducing protein intake from the
normal 1.0 to 2.0 gm/ kg to .5 gm/ kg, along with the
usual dosages of levodopa and an inhibitor. Both
methods, as well as a variety of other drug manipulations, have som e merit; however, this problem rem a in s quite serious.
3. Akinesia paradoxica. Sudden "blocking"
seems to occur, often triggered by a sudden change in
afferent sensory input (as unexpected stress), and the
patient "freezes," often falling. Blood levels of levodo pa are usuall y high , 21 and the theory is that there is

a sudden, unan swered demand on the noradrenalin
" drive" mech a ni sm , now depleted b y involvement of
the locus ceruleus.21 Fortunately, this complication is
quite uncommon, since its man agement and path ogenesis rem a in uncerta in.
In numerous other ways, and in spite of many
drugs, Parkinsonian patients seem to gradually lose
the benefit of medication and deteriorate after a number of years.
Several other facets of the treatment of Parkinsonism deserve special mention. A certain number
of p a tients develop a mild-to-moderate dementi a. 26
This part of the picture does not seem to be wholly
reversible with levodopa and thus becomes part of
the overall management. Discussion of this is beyond
the scope of this paper. Another important part of
present management is physical therapy. The motivation and assistance provided b y this moda lity is of
inestimable value, a nd no experienced clinician
doubts the value of maintaining mobility in the
patient with Parkinsonism . Seriously a ffected patients are best cared for by facilities offering this form
of treatment.
Evaluation of the physician 's trea tment is quite
important, since the probability of eventual failure is
high . With a ny given patient , the ph ysici a n must
establish methods of continuing patient evaluation
that include such actions as rising from a chair, handwriting, drawing whorls, and activities of daily living.17 Once clear reg ression occurs, efforts at combating this, while often futile, must be in stituted , and
a periodic semi-quantitative evaluation of the patient
is useful.
The Future. A number of pharmacologic attempts to alter Parkinson's disease are in progress,
but most show little potential. Two that show the
g reatest possibility of success presentl y are bromocriptine21·28 a nd a pomorphine.
Bromocriptine, a n ergot alkaloid containing a
lysergic-acid residue, activates dopam inergic recep. tors. The evidence cited is but a single study in which
19 patients received an optimum dose of 20 to 75 mg
d aily; the original study consisted of 28 patients, but
I failed to follow directions and 8 had intolerable side
effects. Side effects, usually dose dependent, were in
every way similar to levodopa, except for four new
reaction s: erythema, edema, an d tenderness of the
a nkles; burning discomfort of the eyes; diplopi a; and
frequent extrasystoles. Of the 19 who continued
bromocriptine, all but 4 were able to omit their levodopa or levodo pa/ carbidopa. All noted improvement
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of Parkinsonian symptoms while on bromocriptine as
compared to a placebo, but the authors were unable
to draw any conclusion comparing bromocriptine
and levodopa. The drug a ppears to have some
promise, particularly since it obviates the necessity of
having endogenous dopa decarboxylase, which is also
depleted in the striatum of Parkin sonian patients as
the disease progresses.
A second drug offering some promise is N-propylnoraporphine, an analog of apomorphine having
a nephrotoxic dose far in excess of its therapeutic
dose.29 In the series by Cotzias et al, 29 all 24 patients
improved, and the "On-Off" phenomenon of 6
patients, still present on N-propylnoraporphine
alone, was abolished by co-administration of alphamethyl dopahydrazine. Side effects, including drugrelated ren a l toxicity in two patients, were not uncommon, a nd further evaluation is necessa ry.
Summary. While an exhaustive review of avai lable management has not been attempted, the frequently missed differential diagnoses and important
therapeutic modalities have been discussed . No treatment seems to stay the inexorable progression of this
disease, but several avenues offer the patient a better
quality of life as the disease proceeds.
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Episodic Disorders of Vision
JOHN W. HARBISON, M.D.

Professor, Departments of Neurology, Neurosurgery and Ophthalmology, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia
Introduction.
Of all our senses, vision is most commonly associated with patient distress, if not overt alarm, when
abruptly compromised.
Despite patient concern, a rare, or rarely recognizable, clinical entity is perhaps of less significance
to the physician than to the patient. When the broad
spectrum of episodic disturbance of vision is closely
examined, it becomes apparent that these visual
symptoms are indeed of common occurrence in the
population at large.
Surprisingly, despite their ultimate effect on the
eye, a majority of the clinical entities that produce
episodic disturbance of vision are neurologic (Fig 1).
Episodic is defined as being " ... made up of
separate, loosely connected episodes."* In turn, an
episode is " .. . a usually brief unit of action ... an
occurrence or connected series of occurrences and
developments which may be viewed as distinctive and
apart, although part of a larger or more comprehensive series."*
In binocular man, episodic visual change has
two essential parameters of basic diagnostic significance: Time and laterality.
In terms of time, an episode has both duration
and frequency. Although both characteristics are of
diagnostic value, duration is the one most frequently
used in discussing disorders of vision. Episodes may
vary in duration from seconds to as long as months
(Fig 1).
A no less important element is the laterality of

the visual event. Laterality is obviously restricted to
right or left, a fact, however, which does not detract
from its localizing value. Apart from laterality, yet
closely related, is a further obvious fact: The eyes
may be episodically involved independently or simultaneously . This too has great localizing value.
The entities that produce episodic visual disturbance will be considered in sequence of timing, beginning with those of brief duration and progressing to
those of prolonged duration. Within each specific
time unit the importance of laterality will be considered.
Visual Disturbances Lasting Seconds.
Obscurations. An obscuration is a brief alteration of vision. It may occur monocularly, but generally it is binocular. It usually lasts from 5 to 10
seconds, but it may continue for up to 30 seconds
(Fig 2). Obscurations are usually frequent, occurring
numerous times weekly if not daily. They may con-
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Fig I-Graphic display of the time durations of all episodic disorders of vision.
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Fig 2-Graphic display of the time duration range of obscurations.

tinue over extended periods, their ultimate duration
depending upon the course of the inciting illness.
They seem to be infrequently brought on by posture
or activity and are classically unpredictable.
A variety of terms are used in patient descriptions of obscurations. A popular description is that of
" ... a graying out of vision. " ' They are also called
blackouts, fade outs, a nd simply blurring. They have
been compared to fog, mist, and opaque curtains.
Obscuratio ns are usually isolated events, unassociated with other neurologic or visual symptom s. Because of their very brief durations, they are less
alarming than other episodic disturbances of vision.
Two causes of obscurations are presently recognized : Papilled e ma a nd vertebra-basilar insufficiency."2 The differentiation of these two sources
is simple a nd rests almost entirely upon the presence
or a bsence of papilledema.

Fig 3-Example of severe papilledema resulting in obscurations.
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When obscurations result from papilledema, the
optic disc changes are nearly always severe (Fig 3).
The obscurations of papilledem a may be monocular
or binocular. Their origin is presumed to be ischemia
of the optic disc, secondary to the increased intracranial pressure. It is common to find additional
signs and symptoms of increased intracranial pressure in patients presenting with obscurations of papilledema. These include headache, nausea and vomiting, and often diplopia. The incidence of focal
neurologic signs is much less common a nd when present ominously suggests a mass lesion. Most patients
in this group are young, reflecti ng the possibly single
most frequent etiology of the increased intracranial
pressure-pseudotumor cerebri.
.
Patients presenting with obscurations as a manifestation of vertebra-basilar insufficiency are, not surprisingly, much older. Here, obscur.a tions are al.w~ys
bilateral and imply bilateral ischemia of the occ1p1tal
cortex. Obscurations may be the only manifestation
of transient ischemia in the vertebra-basilar arterial
distribution , or they may be one of many. Other
manifestations include dizziness, diplopia, facial paresthesias, dysarthria, weakness, and ataxia. These
symptom s most commonly occur independently. Although they may presage a stroke in the vertebrobasilar arterial distribution, this relationship is
unpredictable. Patients with obscurations of vertebrobasilar origin never have papilledema.
Obscurations per se are merely of diagnostic
value and do not require treatment. Although papilledema may progress to blindness and optic atrophy
the obscurations themselves do not reflect what the
ultimate visual status will be.
Treatment should be directed at the etiology of
the obscurations. In those associated with papilledema, a mass lesion must be ruled out or pseudotumor cerebri confirmed. Appropriate a nd specific
therapy may then be initiated. If the obscuration is of
vertebra-basilar origin, one must frequently evaluate
the propriety of anticoagulatio n. In both circumstances ap propria te therapy usually results in symptomatic resolution.
Visual Disturbances Lasting Minutes.
In differentiating the causes of episodic disturbances of vision lasting for minutes, discrete duration and laterality are of p ara mo unt importance.
Amaurosis Fugax. When the transient loss of
vision occurs monocula rly it is popularly referred to
as amaurosis fugax-fleeting blindness. 3 - 8 This clini-
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ca l event is characteristically of abrupt onset; it seldom evolves in a progressive fashion. Its duration
may be variable, lasting from one to several minutes ,
but the mode seems to be from one to three minutes
(Fig 4) . It is often difficult to establish the time sequence as concretely as one would like, since patients
frequently lose the perspective and scale of time. The
degree of visual loss varies from complete to only
moderate blurring, and altitudinal visual loss is not
infrequent. A sensation of color may accompany the
visual loss, but photopsia or scintillations are rare.
The resolution of the visual disturbance is generally
as abrupt as its onset and usually complete without
residual loss of acuity or field .
The episodes may recur many times per day or
be separated by days , weeks, or months. They typically occur in isolation without associated neurologic
symptoms, although additional transient signs of internal carotid ischemia such as hemiparesis, sensory
change, and aphasia may occur independently .
The overwhelming majority of patients presenting with amaurosis fugax will harbor extracranial
internal carotid artery disease of atherosclerotic origin with precise localization to the common carotid
bifurcation (Fig 5). Although amaurosis fugax may
be "the hallmark of carotid insufficiency, " a wide
variety of other sources exists. These include increased
intraocular pressure; that is, glaucoma, arteritis of
the branches of the ophthalmic artery; g ian t ce ll or
temporal arteritis, alteration of numerous elements o f
the blood , red cells and proteins particularly , and
thromboembolic events of cardiac o rigin such as
mural thrombi, valvular vegetation of infectiou s or
noninfectious origin, and tumor emboli.

Fig 4-Graphic display of the time duration ran ge o f amauro sis
fugax.
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F ig 5- Lateral angiograp hi c demonstration of ex tracra nial interna l carotid a therosc leroti c disea se (arro•v) productive o f a maurosis
f ugax.

As by far the most common etiology of amaurosis fugax is atherosclerotic disease of the carotid
bifun.:at ion, it is appropriate to direct diagnostic consideration to this focus.
The presence of a focal bruit over the carotid
bifurcation at the angle of the jaw has been found to
be strong evidence of disease . A bruit , however, may
not be present even with significant disease and occasio nally it may be falsely localizing with the significant changes occurring in the contralateral carotid.
Asymptomatic bruits, although evidence of some degree of disease , should rarely be pursued diagnostically .
C hanges in the ca rotid pulsation in the neck are
seldom helpful. Often the external carotid overlies the
internal carotid and masks changes in the latter vessel's pulsation.
Single or multiple bright refractile cholesterol
emboli found in the ipsilateral retinal arterioles are
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Fig 6-Fundus photograph of cho lesterol emboli (arrows) .

strongly indicative of a carotid o rigin for amaurosis
fugax. 9 • 10 Less apparent whitish platelet plugs may
a lso be seen. These emboli often lodge in bifurcations
of vessels distal from the optic disc, thus requiring
pupillary dilatation and careful funduscopic examination for identificatio n (Fig 6).
The use o f ophthalmodynamometry, Doppler
flo w studies, and therm ogra phy provide additional
pieces of incriminating evidence. It remains, however,
for carotid angiogra phy to confirm the presen ce, extent , and significance of bifurcation atherosclerotic
cha nges (See Fig 5).
The identification of the other less common
causes of a maurosis fugax is seldom difficult if their
possibility is recognized.
Treatment should be directed at the ca use o f the

Fig 7-Fundus photograph of cloudy retina l edem a (arrow) seconda ry to a central retinal artery branch occlusion with infarction.
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Fig 8-Graphic display of the time duration range o f migraine.

amaurosis fuga x. A significa nt incidence of stroke in
the interna l carotid a rtery distribution including the
retina follows premonitory ama urosis fugax (Fig 7).
In carotid bifurcation atherosclerotic disease we at
the Medical College of Virginia have favored enda rterectomy when appropriate. The p rim ary obstacle to endarterectomy has been significant symptomatic cardiac disease. In this situation, anticoagulation may b e advisable .
Migraine. Typical amaurosis fugax which consisten tly lasts from IO to 30 minutes sho uld suggest
the likelihood of a migrainous origin (Fig 8).
The recognition of visual phenomena as the forerunner of migraine dates to antiquity 11 ; t he variety of
these visual hallucinations is remarka ble.12 • 13 It is a lso
clear that the visual aura may constitute the sole manifestation of a migraine attack . 14 If indeed the visual
aura is never followed by the hemicranial, vascular
headache, nausea, and diffuse autonomic disturbance,
one may have diffic ulty in recognizing its migrainous
character. That this specific circumstance mimics
a ma urosis fugax seems well established. 14 Certain features of the clinical presentation are useful in identifying these admittedly uncommon cases of migraine.
Typically, the event recurs in an identical fashion
over many years. It commonly begins under the age
of 20. The expected heredita ry aspect of migraine is
frequently a bsent and the relationship of the visual
event to the headache may become so inconstant as
to appear to have no connection-so-called dissociated migraine. In some cases, headache may
never occur. The most important feature, however,
remains the duration . A maurosis fugax as a manifestation of complicated migraine almost always lasts
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between 10 and 30 minutes. It is comrr
presentation to resolve as the patient ac
the 20's and 30's and be replaced by r
migraine.
Vertebra-basilar Insufficiency. Whe
loss of vision of minutes in duration occu1
the source most commonly is in the vert
arterial distribution. 2 Although amauro
internal carotid origin conceivably might
erally and synchronously, this must ind
Obscurations, the momentary visual loss
onds cfue to vertebra-basilar insufficienc
discussed above. More commonly, ho1
sient visual loss secondary to ischemia
tebro-basilar distribution lasts one to fi
With the increase in duration of the vi:
ment, patient concern is, understanda
cantly increased. This in itself may ace<
greater frequency with which these vist
reach the physician's attention. The e'
visual loss is variable from a simple per•
of central vision to total blackout.
In common with patients presenting
rations of vertebra-basilar origin, this p:
tends to be elderly. The association o
symptoms of brain stem origin occurring
pendently or synchronously is to be antic
would again expect historical evidence
dizziness, vertigo, diplopia, dysarthria, a
and bilateral extremities paresthesias as"'
ness.
The implied risk of stroke in the vert
arterial distribution in this patient group
those manifested simply by obscuratio
eration of anticoagulation is appropriat
few highly selected patients presenting <
history of symptom precipitation by nee
or position and confirmed by angiogr:
surgery directed at decompression of C•
vertebral arteries in the cervical spine m<
ered (Fig 9). This patient population is t
nificantly younger than the average patit
tebro-basilar insufficiency, and frequent!)
trauma is clearly evident.
Basilar Artery Migraine. In a mann
amaurosis fugax, when transient bilater:
pairment occurs with a duration of frc
minutes, a migrainous etiology becomes
(See Fig 8).
Basilar artery migraine has been wel
and adequately described for some tim
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ig 9-Subtracted lateral view of a vertebral angiogram demonrating arterial compromise (arrow) by osteoarthritis in the cereal spine, which resulted in visual loss.

iarked tendency to occur in a recognizable pattern.
t is most common in adolescent girls. Visual symp-

Jms are the most common initial event with the
isual disturbance varying from total loss of vision to
lurring of central vision. Positive visual manifestaons characteristic of migraine may be totally absent.
.ssociated vertigo, ataxia, dysarthria, and sensory
aresthesias are common. Characteristically, a severe
hro bbing occipital headache often accompanied by
ausea a nd vomiting follows. As with the migrainous
maurosis fugax, however, headache may not occur.
Generally the clinical pattern is such that doubts
.f its migrainous origin do not arise. Once again
here is a tendency for these attacks to be replaced by
10re classic migraine as the years pass.
Visual Disturbance Lasting Hours.
Episodic disturbance of vision lasting hours
eems to be less often recognized if not actually less
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Fig JO-Graphic display of the time duration range of episodic
visual loss secondary to uncontrolled diabetes mellitus.

common. Some o f the sources of visual symptoms
measured in hours are extensions of previously discussed entities. Some, however, are entirely new and
distinct.
Diabetes M ellitus. The incidence of episodic visual disturbance lasting hours in dia betes mellitus is
unclear (Fig 10). It is quite likely that early diagnosis
and improved drug control has significantly reduced
the magnitude of these visua l symptoms if not their
incidence.
Sudden bilateral blurring of vision is well known
to occur in patients with diabetes mellitus.' 6 •17 It has
on occasion been the initial symptom leading directly
to the diagnosis in a previously unrecognized case.
More commonly it occurs in established diabetic
patients; its basis is known to be abrupt refractive
changes in the eye of either myopic or, hypermetropic
nature. The refractive change seems rather clearly
related to blood sugar levels; myopia occurring in the
presence of hyperglycemia a nd hypermetropia with
hypoglycemia. It may, in fact, be useful in alerting the
physician to ineffective diabetic control.
The visual disturbance is described by the
patient as blurring with impairment of central vision.
In all circumstances it can be corrected by appropriate refraction . At the bedside the use of a pinhole
may prove the refractive nature of the visual change
to the satisfaction of the physician .
The precise mechanism by which the blood sugar
level effects the abrupt refractive change is not entirely clear. It i ~ postulated, however, to be the result
of secondary changes of lens hydration.
The course of visual blurring in poorly con-
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trolled diabetics is transitory, lasting variable periods, usually measured in hours to a few days . It is
<:!lmost invariably reversible. Occasionally cataracts
may develop abruptly in this group of patients. 17
Therapy of this episodic visual disturbance
should be directed at more effective diabetic control
rather than refractive correction by virtue of its transitory nature.
Post-traumatic Blindness. A second transient
visual disturbance typically lasting hours which although probably uncommon is often unrecognized is
post-traumatic or concussion blindness (Fig 11 ).
This transient bilateral visual loss seems clearly
of occipital cortical origin. It is also quite certainly
causally related to preceding head trauma. Children
appear to be much more susceptible to post-traumatic blindness than adults. 18·!9 IPP 23 s• - 23851 The degree
of trauma necessary for the manifestation of this
syndrome is markedly less in children where relatively minor head injury, usua lly occipital in nature,
and unassociated with unconsciousness or skull fracture, has resulted in post-traumatic blindness. In
adults the injury is frequently much more severe with
unconsciousness and skull fracture the rule.
The visual disturbance is commonly severe with
early tota l loss no t unusual. The course of recovery is
sim ilar in both children and adults; there is generally
progressive return of vision to normal over a period
of from one to three hours. Permanent residual disturbance may or may not occur and generally reflects
the magnitude of the occipital injury. The currently
accepted mechanism of visual loss is felt to be occi-

Fig I I-Graphic display of the time duration range of post-traumatic visual loss.
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Fig 12-Graphic display of the time duration range of episodic
visual loss secondary to stroke.

pita! lobe-visual cortex concussion. Treatment is usually expectant requiring only observation.
Stroke. Final consideration in visual disturbances lasting hours should be given to those episodic
disorders of vision previously discussed where the
transient ischemia, whether localized to retinal vessels, internal carotid artery, or vertebra-basilar system, whether of atherosclerotic, systemic, or migrainous origin, ceases to be transient and results in
more prolonged visual deficit (Fig 12).
An arbitrary point has been established at 24
hours which is used to separate transient ischemic
attacks from strokes. As with most other artificial
guidelines, much variation occurs in clinical practice.
We therefore regularly classify as strokes events
which last from 12 to 24 hours to three and more
days.
Common to the majority of these events is a
history of preceding episodes of transient visual disorder. These include obscurations, 2 amaurosis fugax, 8
and transient cortical visual loss, 3 as well as classical
migrainous events of either monocular or binocular
character.12 Not infrequently, although resolution
may be nearly complete, residual loss of visual acuity
or field may remain, emphasizing that a stroke has
occurred.
Retinal strokes basically consist of central retinal artery and central retinal artery branch occlusion.9 The latter is obviously the most frequent retinal
stroke to resolve.
The onset is classically abrupt with complete
monocular visual loss. Characteristic of these events
is funduscopic evidence of retinal ischemia. This usu-
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ally is greyish retinal edema stopping short of the
classic cherry-red spot of irreversible central retinal
artery occlusion (See Fig 7). Recovery often begins
within an hour or so and evolves over several hours .
Residual visual acuity changes may vary from slight
to severe and visual field changes are characterized
most commonly by altitudinal or sector field loss.
Treatment should be directed toward the usually
neglected internal carotid bifurcation disease (See Fig
5). Prompt therapy may avoid a tragic repetition
resulting in permanent blindness.
Total occlusion of the cervical internal carotid
artery at its bifurcation with the external carotid may
result in a wide variety of clinical manifestations. On
the one hand, a devastating hemisphere infarct with
hemiplegia and aphasia may occur; on the other, the
patient may note only the transfer of his odd, neck
bruit from one side to the other and cessation of the
bothersome episodes of transient monocular blindness. Between these two extrem~s, an episode of prolonged visual impairment of hours' to days' duration
may occur. The clinical picture may so resemble that
described for retinal strokes as to defy separation.
Of significant value in placing the inciting event
in the internal carotid artery is the reversed bruit and
an ipsilateral Horner's syndrome (Fig 13 ).
It is quite common for the focal bruit of internal
carotid bifurcation disease to cease with occlusion of
the artery. It is likewise frequent fo r a focal "increased flow bruit" to be either accentuated or become initially manifest over the contralateral internal
carotid bifurcation. At the same time, in about 15%
of internal carotid occlusions, edema of the arterial

Fig 13-Right-sided miosis and ptosis of Homer's syndrome secondary to internal carotid artery occlusion.
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Treatment again should be directed at prevention of repetitive strokes with anticoagulation, the
most popular if not the most effective therapy .
The occurrence of permanent residual defects of
vision following typical complicated migraine involving retinal , carotid, or basilar arterial distributions is well established, although rare. 12 The clinical
circumstance is readily recognized by the presence of
a long history of preceding typical repetitive episodes
of visual disturbance suggesting a migrainous basis.
The mechanism whereby a benign migrainous event
is transformed into a permanent stroke is unclear.
Therapy has been ineffective.
Fig 14-Graphic display of the time duration range of optic neuritis.

wall involves the vasa vasorum of the carotid sympathetic plexus resulting in an ipsilateral Homer's syndrome characterized by miosis and ptosis without
anhidrosis (See Fig 13 ). The other clinical hallmarks,
as with retinal stroke, may consist of funduscopically
visible retinal edema, variable visual acuity loss, and
field defects of attitudinal or sector character.
Diagnostic confirmation is angiographic. U nfortunately, therapy is ineffective, emphasizing the need
of early clinical recognition of internal carotid arterial disease.
Strokes in the vertebra-basilar arterial distribution regularly result in prolonged visual loss lasting
hours to days. Restitution of some visual function,
however, is the rule. The association of additional
neurologic deficit of brain stem and cerebellar origin
is highly variable.
The onset of the bilateral visual loss is similar to
a transient ischemic attack, which commonly has preceded the stroke by days to months. On this occasion,
however-, the vision does not improve promptly and
blindness remains . Characteristically, vision begins to
return in hours to a few days. In this time period the
patient may experience a variety of visual phenomena
including either crude or complex visual hallucinations and visual distortion.
Visual acuity not infrequently achieves remarkable recovery. Residual visual field defects of homonymous character, either hemianopic or quadrantinopic are frequent. It is not unusual for the
patient to experience enduring visual agnosias of diverse nature including color-naming defects, and agnosias for faces, places, and even food.

Visual Disturbance Lasting Days to Weeks.
A discussion of episodic visual disturbance lasting days to weeks becomes essentially a discussion of
optic neuritis (Fig 14 ). There are unusual exceptions
to this dictum which will be discussed subsequently.
Optic Neuritis. Optic neuritis is a misleading
term. Its implication of an infectious or inflammatory
basis of optic nerve disease is rarely accurate. Although bacterial and viral disease of the central nervous system and orbital contents occasionally results
in optic nerve dysfunction, the ciinical picture does
not correspond in most circumstances with the general definition of optic neuritis. The systemic symptomatology, clear evidence of inflammatory orbital
or central nervous system (CNS) disease as well as a
more fulminant, frequently irreversible optic nerve
injury, generally serve to distinguish this truly infectious optic neuritis from the more common clinical
picture.
The clinical definition commonly used for optic
neuritis is that of rapidly developing blurring of vision with or without pain about the eye or on movement of the eye.20 • 21 It may occur either monocularly
or binocularly. There is a tendency for binocular
involvement to be most frequent in children. 22 The
degree of visual loss is variable; however, loss of
central acuity greater than 20/ 200 is the rule. The eye
is normal on examination. Visual field evaluation
should demonstrate field loss, most commonly in the
form of a central scotoma. The funduscopic examination may be normal or reveal disc swelling and
elevation with or without hemorrhages and exl.idates.
Disc pallor is rare and if present should suggest previous bouts of optic neuritis whether or not a confirmatory history is available. Optic neuritis most
commonly occurs in isolation without associated
neurologic symptoms or signs.

HARBISON: EPISODIC DISORDERS OF VISION

The episode of optic nerve dysfunction tends to
last from a few weeks to a few months. Total resolution is not uncommon, particularly from an acuity
standpoint, but mild residual defects are not infrequent. Further episodes occur in a minority of
cases, but may do so on multiple occasions.
The age of onset of optic neuritis varies tremendously from the pre-teens to the 70's and, rarely ,
80's. 23 The median age in most studies has been about
30.
Optic neuritis has been characteristically classified as either typical ·o r atypical. The typical patient is
a young patient generally in the 20's, fulfilling rather
closely the criteria already presented, with monocular
involvement. The atypical patient generally falls outside the 20- to 40-year age group, and develops visual
loss in either an abrupt fashion or progressively at a
slower pace. Visual acuity is either insignificantly involved or severly impaired . Commonly, the episode
of visual disturbance fails to remit or does so very
incompletely in the expected period of days to
weeks. Associated symptoms and signs of neurologic
or medical disease are distinctly more frequent.
Within that group of patients with optic neuritis
characterized as typical is a second subdivision. This
is based upon the presence or absence funduscopically of disc edema and elevation . In the absence of
disc changes, the optic neuritis is termed retrobulbar
neuritis. In its presence, the optic neuritis becomes
papillitis. This designation has little if any implication
with regard to etiology or prognosis. 20
If a specific etiology is not identified, it is common to assume that the optic neuritis is a harbinger
of multiple sclerosis. Sufficient long-term studies are
available to place the association of optic neuritis and
multiple sclerosis in true perspective. It is now relatively clear that only one in six patients with optic
neuritis can be expected to develop typical multiple
sclerosis in the future. 20 ·21 This incidence of about
15% is significantly lower than prior incidence rates
frequently placed nearer 50%.24 ·25 Armed with this
reduced statistical probability the physician can refrain from a discussion of multiple sclerosis and the
psychological impact it carries with a much clearer
conscience.
The potential etiology of remaining cases of optic neuritis is legion and virtually reads as an index of
medical and neurologic disease.23 Not surprisingly,
however, a very substantial number of cases of typical optic neuritis remain of so-called idiopathic origin.
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The identification of those cases of optic neuritis
for which a firm etiology can be achieved is frequently linked to a more atypical presentation: binocular instead of monocular involvement; a young
or elderly patient; and, perhaps most importantly, the
association of additional medical or neurologic signs
or symptoms.
The treatment of optic neuritis, typical or atypical, has been , and remains, an area of controversy.
Obviously if a specific inciting etiology can be identified, therapy should be based on the diagnosis. In
those cases classified as idiopathic, as well as those
suspected to be premonitory of multiple sclerosis, it
has been common to use adrenal corticosteroids;
their efficacy remains controversial and many competent physicians do not use them. When adrenal
corticosteroids are used, it is common to begin with
a high dose, from 60 to 100 mg daily, and follow a
rapidly tapering course over two to three weeks.
Little if any difference in efficacy has been detected
with the preparation used or the mode of administration. Prednisone, an inexpensive preparation taken
orally, a simple painless mode of administration, is
not an unreasonable approach if one wishes to treat a ,
given patient.
A diagnostic pitfall occurs in a group of the
atypical optic neuritis cases based upon their occasional response to adrenal corticosteroid therapy.
Cases of optic neuritis ultimately found to be caused
by sarcoidosis, meningioma, pituitary adenoma, and
carcinomatous leptomeningitis may occasionally improve dramatically with steroids. This has led to diagnostic errors. In nearly every instance the optic neuritis has been atypical. Thus atypical features in optic
neuritis should suggest diagnostic caution.
The typical course of optic neuritis has been one
of resolution with or without a residual defect of
variable nature and degree in from a few days to
many weeks . Treatment with adrenal corticosteroids
has been believed capable of hastening resolution but
probably incapable of improving final function.
Post-epileptic Blindness. One final cause of episodic visual disturbance lasting from days to weeks is
postictal amaurosis (Fig 15). Although this particular
clinical entity occurs rarely, its occurrence can cause
extreme consternation if the etiologic mechanism or
association is unrecognized.
Postictal amaurosis of cortical origin has been
repeatedly observed in young children and infants.191vv121 - 1291·26 The convulsive episode has typically been violent. The blindness may be associated
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Fig 15- Graphic display of the time duration range of post epileptic blindness.

with aphasia, deafness, or hemiplegia . Visual loss has
typically lasted from days to weeks with slow, progressive recovery . The mechanism of its production
remains unclear. No satisfactory therapy has been
identified.
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Summary.

A diverse and seemingly unrelated group of diseases has been integrated on the basis of their episodic disturbance of vision. The parameters of laterality, but more importantly the duration of individual
,episodes, have been used to direct diagnostic consideration. Many of these clinical entities are commo nly
encountered in practice. Their recognition and care
are dependent upon prompt diagnosis based upon
characteristic clinical signs and symptoms.
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An Approach to Dizziness
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Dizziness is a vague and ubiquitou s sym ptom
which frequently frustrates and perpl exes the clinician . Di zz iness in the broad sense implies any unpleasant se nsa tion of di sturbed relation ship to surrounding objects. A number of sy non y ms such as
faintness, light-headedness. gi ddiness, a nd swaying ,
although descr iptive . are often no more speci fic.
Problems in diagnosis , therefore, are due not only
to the arn biguity of the term but also to the wide
spectrum of disorders in w hich di zzi ness m ay be a
prominent symptom. Although disorders of the vestibular system usually receive primary attention, it
should be kept in mind that many neurologic, cardiovascular, p sychiatric, and other disorders a re not infrequently associated with dizziness.
The term ver tigo, on the o ther hand, is specific
and ma y be distinguished from other forms of di zziness in th a t it implies a d efinite rotational sensation
or illusion of motion. Although it is often impossible
to make a differentiation between vertigo a nd other
types of dizziness in the individual patient. the distinction is important as vertigo specifically reAects
dysfunction in the vestibular system.
The purpose of this pa per is to review the anatomy and physiology of the vestibular system, to discuss the most common clinically significant causes of
di zziness, and finally , to consider the practical office
evaluation of the dizzy patient.
The Vestibular System. A b as ic und ersta nding of
the anatomy a nd physiology of the vestibular system
is necessary in order to understand the procedures
employed to test its integrity as well as the clinical
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ma nifestation of its dysfunction. The vestibular system includes the end organ (semicircular canals and
otolith system), a portion of the eighth cranial nerve,
and the vestibular nuclei in the brain stem. 1 Fibers
from the ves tibular nuclei project to the cerebellum,
skeletal muscul a ture, extraocular mu sc les, and un doubtedly to the cerebrum. The precise connections
to the cortex are unknown , although vestibular representation in the posterior temporal lobes is suspected.
The ves tibul ar apparatus serves as the primary organ
of eq uilibrium comb inin g with v isual a nd other sensory stimuli to provide sensa tion of motion and spatial orientation . The vestibular system also functions
in the control of skeletal muscle ton us and in stabilizin g the eyes during head movements . In the steady
state, there is equal tonic neura l input from the two
end o rgan s. With rotation a l movement, the semicircu lar cana l in the plan e o f movement is stimulated ,
leading to a change of neural activity in the brain
stem, which is projected to the cortex to produce the
appropriate conscious sense of rotation . A disease
sta te w hich changes the firing frequency of the end
organ , or the neural input from the brain stem , causes
ver tigo. In such cases the cerebral cortex is seemingly
deceived by the brain stem input and interprets it as
rotational movement. 2
Vestibular dysfunction may be classified as peripheral or central , the dividing line being where the
eighth nerve enters the brain stem. Peripheral disease
is generally felt to be most common and is not infrequently associated with a hea ring disturbance due
to the close anatomical relationship between cochlear
and vestibular portions of the inner ear. A patient
with unidirectional jerk nystagmus, vertigo in the direction of the first component, past pointing, and falling in the direction of the slow component is probably suffering from acute dysfunction of the end
MCV QUARTERLY 12(3): 110-115, 1976
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organ on the side of the slow phase. Bidirectional
nystagmus varying with direction of gaze, vertical
spontaneous nystagmus, past pointing, and falling
toward the fast phase points to brain stem disease. 2
Vertigo is usually more intense with peripheral disorders and is commonly associated with nausea and
vomiting.
Positional vertigo refers to the vertigo and accompanying nystagmus which occurs after the head is
placed in a particular plane. Peripheral and central
forms of positional vertigo have also been described,
based on the characteristics of the nystagmus induced.2 In the peripheral type, a latency of 3 to 40
seconds is observed between attaining the precipitating head position and the onset of nystagmus. If
the head remains in this position , the nystagmus will
decrease or fatigue after 30 to 60 seconds. Gradual
habituation of the nystagmus occurs with repetition
of the aggravating position and reproducibility is
poor at any given examination. With central pathology , the onset of nystagmus is immediate and fatigue
and habituation do not occur. Again, vertigo is generally more severe with peripheral disorders.
Otolaryngologic Causes of Dizziness. A variety of
otologic disorders ranging from impacted cerumen,
and otitis media to otosclerosis and trauma to the
labyrinths may produce dizziness. This discussion
will be limited to the more common and clinically
significant disorders .
Meniere's disease or endolymphatic hydrops is
predominantly a disease of middle-age or older, and
is unilateral in 90% of cases. The onset is usually
insidious, frequently beginning with tinnitus, fullness
in the ears, and Auctuating hearing loss. The hallmark of the disease is episodic vertiginous spells usually lasting between 2 and 24 hours. During the attack, pain or numbness may be noted in the affected
ear as well as diminution of auditory acuity. Spells
recur at irregular intervals varying from days to
years .a
The majority of patients with positional vertigo
suffer from benign positional vertigo.4 In this type,
hearing and caloric responses are normal and transient symptoms occur only with assumption of acertain head position. The greatest incidence is between
40 and 60 years of age and symptoms often clear
spontaneously within one year. The etiology is unknown.
Acute labyrinthitis may occur as a result of acute
or chronic otitis media and is manifested by vertigo,
nyst,agmus, severe hearing loss, nausea, and vomit-
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ing . Toxic labyrinthitis is usually secondary to ototoxic antibiotics such as streptomycin. Typical vertigo may not occur since both labyrinths are equally
depressed. The primary manifestation may be difficulty walking with staggering and inability to stay on
course. Hearing loss and high-pitched tinnitus may or
may not occur.
Vestibular neuronitis or viral labyrinthitis is primarily a disease of young adults which frequently
exists in epidemic form. This disease may be defined
as a sudden vestibular crisis lasting days or weeks
with partial or total loss of vestibular function in one
ear without auditory involvement, and without recurrence.a The prolonged period of the attack and the
absence of hearing loss and recurrence distinguish
vestibular neuronitis from Meniere's disease.
Neurologic Causes of Dizziness. A caustic neuromas are the most common of the cerebellopontine
angle tumors comprising approximately 5% of all
intracranial tumors. Early symptoms are usually vestibular and cochlear, but the latter usually appear
first. The onset of unilateral high-frequency hearing
loss and high-pitched tinnitus is often insidious. Vertigo is usually not a prominent symptom and most
patients complain of transitory, but progressive,
vague dizziness and unsteadiness which is aggravated
by movement. 5 This may be explained by the slow
expansion of the tumor which allows time for the
vestibular nuclei to compensate for the disturbance. 6
Associated signs of involvement of the seventh, sixth,
and fifth cranial nerves and cerebellum are usually
late, although such signs should be sought and are
diagnostic when present.
Although the sudden onset of dizziness is a frequent symptom of vertebra-basilar cerebrovascular
disease, it rarely occurs in isolation without other
symptoms of neurologic dysfunction such as diplopia, dysarthria, facial numbness, or hemiparesis.
C. M. Fisher points out that dizzy spells that continue more than six weeks without accompanying
symptoms are almost never cerebrovascular in nature.7 There seems to be an unwarranted tendency to
attribute mild giddy spells in elderly persons to
"hardening of the arteries. "
Dizziness is a frequent and often early symptom
in multiple sclerosis. Like cerebrovascular disease,
however, other signs and symptoms such as visual
blurring, diplopia, ataxia, paresis, and paresthesias
are almost always present. According to some authors, multiple sclerosis is the most common cause of
the central type of positional nystagmus .6 A unique

112
fea ture in this di sease is the frequent di ssociation of
vertigo and nystag mus.
Vertiginous sy mptom s m ay occur as icta l phenomena in pa tients with seizures of temporal lobe
origin. In such cases consciousness is usua lly impaired , mom enta ry amnesia is often noted , and nystagmus does not occur. Some patients complain of
being hurled into space as if in a tornado .
Cardiovascular Causes of Dizziness. The cardiovascular causes o f di zziness have in common the producti o n o f symptom s by a rrest o r d iminution of cerebral perfusion. With orthostatic hypotension, the
pa tient experiences light-headedness, unsteadiness,
a nd occasionally syncope upon suddenly assuming an
erect position. This syndrome may be idiopathic,
however, it is often secondary to prolonged bed confinem e nt , a nti-h ypertensive agents , or impairment of
sy mpathetic vaso motor reflex acti vity . Such a ttacks
a re usua lly acco mpanied by pa ll o r, tachyca rdia, a nd
sweating as well as the obvious drop in blood pressure. Cardiac disorders ranging from mechanical obstruction to .alterations in cardiac rate or rhythm cari
impair cerebral blood flow and may produce vertigo
and di zziness. In aortic stenosis, the o nset of sympto m s is usua ll y related to sudden position ch a nge . In
additio n, a lm ost a ny a rrh yt hmi a m ay produce vertigo a nd di zziness . The patient may state in such cases
th a t his dizzy episode is associated with a detectable
change in cardiac rh ythm. Overactive autonomic refle~es ma y also result in dizziness followed by syncope. H ypoten sio n a nd bradyca rdia may be triggered
by an emotional or pa inful stimulus as in vasovagal
syncope or be precipitated b y micturition , p a roxysm a l coughing, o r compression of the carotid sinus in
the neck. An impending feeling of syncope characterizes di zziness of cardiovascular etiology.
Anemia an d hypoglycemia should 'a lso be considered a mong the systemic causes of di zziness.
Other Causes of Dizziness. Dizziness is a comm o n symptom in psychiatric diso rders. These
pa tien ts us uall y compl ain of a vague sensation of
light-headedness, which tends to be continuous
rather than episodic and is associated with symptoms
of anxiety, depression, or other hypochondriacal
complaints. Hyperventilation syndrome is a very common cause o f dizziness. a nd th e majority of these
patients suffe r from emotio na l problems. Acute a ttacks of hyperventila tio n produce relatively circ um scribed episodes of light-headedness, frequently with
circumoral and digital pa resthesias and tightness in
the chest. Positional vertigo occurring o nly after hy-
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perventilation has also been reported .a The hypocapnia produced by hyperventilation leads to cerebral vasoconstrictio n and a reductio n in cerebral
blood fl ow .
Drachm an and H art described the occurrence o f
dizziness a mong patients with multiple sensory deficits. a The abnormalities comprising this syndrome
consisted of two or more of the following: visual
impairment (usually cataracts), peripheral neuropathy, vestibular deficits, cervical spondylosis, and
orthopedic a bnormalities interfering with a mbulation . Typically, pa tients were elderly dia betics, who
only complained of light-headedness when walking
and particularly when executing a turn . Dizziness in
this group was most closely reproduced by walking
and turning the head when standing. Drachman and
Hart postulate th at the deprivation of accurate sensory inform ation produces disorientation which is
referred to as di zziness by its sufferers.a
There is considerable disparity between st udies
rega rding the frequency of various causes of dizziness.6 Most reports deal with a selected and limited
segment of the di zzy population . The data compiled
by the Northwestern U niversity Dizziness C linic perhaps best refl ect the incidence of va riou s types o f
di zzin ess in the genera l pop ul a tio n.a This stud y consisted of 125 pa tients with th e co mpla int of di zziness
of a ny type without any selection . A reasonabl y certain diagnosis was claimed in 91 % of cases (Table).
Di sorders of the periphe ral vestibular system proved
to be the m ost com mon cause of di zziness in this
st udy . These patients co mplained of rotational vertigo, fr eq ue ntl y associa ted w ith na usea an d vomiting,
occurring in the absence of evidence of neighboring
brain stem deficits . Among the 38% of patients with
peripheral vestibular disorders, benign positional vertigo occurred twice as frequentl y as a ny other ves-

Table
Major Causes of Dizziness*
Periph era l Vestibular Disorders
Hyperven tilati o n Synd rome
M ultirle Senso ry Defi cit
Psychia tric Di so rde rs
Uncertain Diag nosis
Bra in stem Cerebrovascu lar
Cardiovasc ular
Neurologic Diso rders (others)

38%
23%
13%
9%
9%
5%
4%
4%

* Total is greater than 100% because several patients had more
than o ne diagnosis.
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tibular disorder. Meniere's disease and vestibular
neuronitis each made up 4% of this total. Hyperventilation and multiple sensory deficits together accounted for over one third of the patients . The relative infrequency of cerebrovascular disease
presenting with symptoms of dizziness is pointed out
in the 5% figure . These patients , in keeping with
C. Miller Fisher's statement , 7 all had evidence of
additional neurologic involvement. The absence of
cases of sei zure and acoustic neuroma indicates that
these are rare but nonetheless important causes of
dizziness .
Evaluation. On the basis of the preceding discussion of the pathophysiology and causes of dizziness. we will now consider the clinical evaluation of
the di zz y patient. Many sophisticated and expensive
neurologic and otologic procedures are available. We
shall concentrate, however, on practical office techniques and on indications for specialist referral.
The single most important aspect in the evaluation of a patient with dizziness is a good history,
properly interpreted. Drachman and Hart 8 have
noted that the patient' s subjective experience of dizziness can often be separated into one of four types: 1)
a definite rota tional sensation , 2) a sensation of impending faint, 3) dysequilibrium or loss of balance
with little or no head sensation, and 4) vague lightheadedness other than vertigo, syncope, or dysequilibrium .8 Inquiries need to be made regarding precipitating factors such as relation to posture and motion,
the intermittency or constancy of symptoms, and associated symptoms such as hearing loss, tinnitus ,
nausea or vomiting, and loss of balance. 9 The occurrence of other otologic symptoms (discharge, fullness, or pain in ears) and neurologic symptoms such
as disturbances of vision, speech, motor, and sensory
function should be sought. Past medical history including significant medical illnesses and use ·of medications must be obtained.
In view of the wide variety of disorders in which
di zziness may be present , a complete physical examination is necessary. In addition, special attention
should be directed to certain aspects of the otologic
and neurologic examination . The external auditory
canal should be checked for impacted cerumen or
other abnormalities, and the eardrum carefully examined for evidence of fluid level, hyperemia, bulging,
or perforation . Disturbances of hearing may become
evident during conversation with the patient. Attention should be paid to the level of voice required for
communication, the need for repetition, and the de-
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gree to which lip reading is depended upon . Although
not as sensitive as standard audiometry , the classic
Weber and Rinne tests using an audiometric tuning
fork in the 500 Hz range are most informative. Certain aspects of the neurologic examination should be
emphasi zed . The patient should be observed for past
pointing. In this test the patient stands, extends both
arms, points with both index fingers at the examiner's
index fingers held at shoulder height. and then closes
his eyes. Drift of the hands consistently in either
direction is abnormal. 6 With peripheral disease, the
arms will deviate in the direction of the slow phase of
the nystagmus . Peripheral disturbances will be aggravated by testing the patient with his head inclined
over one or the other shoulder. Past pointing in the
direction of the fast phase or in the absence of nystagmus indicates central vestibular pathology.
Disturbances in gait and posture may be seen in
patients with proprioceptive, cerebellar, and vestibular disorders. The Rom berg test is classically positive
in patients with proprioceptive defects; the direction
of falling is usually variable. With peripheral vestibular disease, the Romberg test is also positive: however, the direction of fall is consistently to one side
and is influenced by changing the position of the
head. Jn cerebellar disease, station and gait are not
remarkably influenced by closing the eyes, and ataxia
is generally in evidence .
Because of the ever-present concern of the insidious cerebellopontine angle tumor, ca reful exal]1ination of the fifth and seventh cranial nerves should
be carried out. The symmetry and strength of the
facial musculature and muscles of mastication need
to be evaluated. The corneal reflex is simple to test
and is most informative. While the patient is looking
upward and to one side, the physician touches the
cornea on the opposite side with a piece of cotton. If
blinking is absent in both eyes, this indicates a loss of
sensation in the cornea tested; if blinking is absent
only in the eye tested, the homolateral facial nerve
may be impaired. Impairment of the homolateral
corneal reflex is frequently noted in cerebellopontine
angle tumors .
One of the most important components of the
evaluation is the dizziness simulation battery. This
battery exposes the patient to a number of situations
that commonly trigger dizziness in an attempt to
simulate the patient's own symptom. These maneuvers include: blood pressure determinations lying and
standing, a standard Yalsalva maneuver for 15 seconds, head turning with eyes open or closed, a sudden
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turn when walking, hyperventilation for three minutes, and the Nylen-B<1rany test. 8 The latter maneuver is a test for positional vertigo. The patient is
abruptly moved from a seated to a supine position
with the head hanging 45° backwards, and turned to
one side and then the other. The patient is observed
for vertigo and nystagmus , noting the onset, duration, and direction of nystagmus.
Another simple technique which can be performed in the office setting is the caloric test. Not
only can vestibular function be assessed by this procedure but also the patient can compare the sensation
produced with his own symptoms. One must first
make certain that the ear canals are free of debris and
that the drums are intact. If available, the use of
15-20( +) lenses or Frenzel glasses will inhibit visual
fixation and magnify the eyes for better observation.
With the patient rec um bent and the head elevated
30°, 3 to 5 cc of ice water are slowly poured into the
ear. The eyes should then be observed for nystagmus
which should be horizontal with the quick component to the opposite side. How well the two sides
agree is most important. A unilateral absent or hypoactive response may be the product of Meniere's
disease, vestibular neuronitis or acoustic neuroma.
Perversion of nystagmus, such as absence of the
quick component, horizontal nystagmus, or a prolonged hyperactive response point to brain stem involvement. It should be emphasized, however, that
one should not try to read too much into the findings
obtained by the caloric testing.
Routine laboratory studies in the dizzy patient
should include: a complete blood count, sedimentation rate, Fasting Blood Sugar (FBS), blood urea
nitrogen (BUN), thyroid function studies, electrocardiogram, and skull x-rays with views of the internal
auditory canals. 8 •9
A more extensive evaluation is often needed.
Patients with objective otologic abnormalities including hearing loss should receive prompt referral to an
otologist for audiologic testing and further diagnostic
studies. The presence of abnormalities on neurologic
examination or the history of ataxia , headaches, disturbance of consciousness, or visual disturbance
would necessitate neurologic consultation. Even in
those patients with transient symptoms or in whom a
benign etiology has been demonstrated, careful follow-up is advisable.
Treatment. The treatment of the dizzy patient
obviously depends on the underlying cause. Since a
benign condition underlies the majority of dizziness
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cases, an important aspect of therapy in these
patients is reassurance. Patients with peripheral vertigo should be informed about vestibular habituation. In other words , the nervous system will ordinarily adapt to an imbalance between the two end
organs and vertigo will ultimately cease. In addition,
since visual fixation has an inhibitory effect upon
vestibular symptoms, vertiginous patients should resist the tendency to close their eyes and should fix a
nearby object. 2 The prophylactic use of drugs for
symptoms of dizziness has not been very gratifying. Most of the information on treatment is
largely anecdotal. Va.s odilators such as nicotinic acid
and betahistine are often recommended; however, I
am unaware of any data that clearly support their
efficacy. Valium® may be beneficial since it apparently exerts some selective sedative effect on the vestibular nuclei. 10
Mecli zine in doses of 25 mg three times a day is
perhaps the most popular and effective medication in
the treatment of recurrent or continuous vertiginous
symptoms. Cohen and Delong" demonstrated in a
double-blind crossover study that meclizine was significantly more effective than a placebo in the treatment of vertigo. There was, in addition, no difference'
in the response of patients with disease of the peripheral or central vestibular systems .
The table is reprinted from Neurology ©1972 by The New York
Times Media Company, inc.
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Management of Transient Brain Ischemia
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Cerebrovascular disease is an exciting subject, so
complex that we could devote 30 minutes to a discussion of aspirin, dipyridamole, and sulfinpyrazone and their potential actions in the prevention of
thromboembolic events. A Classification and Outline
of Cerebrovascular Disease II , published in the Septem her-October 1975 issue of Stroke, depicts this
complexity. The portion labeled "outline" describes
some of the things summarized in this paper.
The first part of the Classification is labeled
"Clinical Stage"; it is where we make contact with
mosi patients, including even those with asymptomatic bruit. The "Clinical Stage" is subdivided into
"Transient lschemic Attacks," "Progressing Stroke,"
and "Completed Stroke." TIA is the abbreviation for
transient focal cerebral ischemic attacks. It has become popular. in the United Kingdom to refer to
syncope as a TIA; elsewhere in the world, however,
the word "focal" must be included in the term transient cerebral ischeniic attack; thus syncope is not
listed urider "Transient lschemic Attacks." TI As are
important because they are warnings of a serious or
progressing or devastating stroke to come . They have
certain significant characteristics: the onset is rapid
(defined as no symptoms to maximal symptoms in
less than two minutes) ; the duration commonly is 2
to 30 minutes. In an attempt to establish a standard,
we state in the Stroke dassification that a TIA can
last as long as 24 hours . Seldom ; however, does a TIA
last 24 hours ; most of us believe that someone who
has a focal cerebrovascular event which lasts 20
hours probably has a small infarct. An attack which
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lasts two to five or ten minutes, as in amaurosis
fugax , has not in that instance produced retinal ischemia to the point of retinal infarction. The same
theory applies to the brain; an attack of short duration does not produce cerebral infarction . The resolution or disappearance of each episode is swift; the
frequency of attacks is variable. Significantly, the
diagnosis is almost always made on the basis of the
history , particularly in office practice. Over 25 years I
have witnessed only a few attacks. Frequently I am
asked, "Did you really complete the study and prove
the diagnosis by doing an arteriogram?" An arteriogram will not reveal whether a patient has had a
TIA or not; it will only display detail concerning the
morphology of the vessels. Anatomically, TIAs are
subdivided into two categories; carotid and vertebrobasilar. With the development of surgical reconstruction for lesions in the carotid system, there is every
reason for making the clinical distinction between
these two symptoms.
The typical history for a TIA in the carotid [arterial]
system is ... :
1. Motor defect (weakness, paralysis, poor use, or
clumsiness of one extremity or of both extremities on the
same side).
2. Sensory defect (numbness including loss of sensat ion or paresthesias involving one or both exremities
on the same side).
3. Aphasia (speech and/or language disturbance
which may be only a minor defect or may be global and
may or may not include difficulty in reading , writing, or
performing calculations).
4. Loss of vision in one eye or in p art of one eye
when vision in both eyes was intact (amaurosis fugax).
5. Homonymous hemianopia.
6. Combinations of the above.
These clinical phenomena generally represent a decrease or absence of function. When th ere is a sensory
MCY QUARTERLY 12(3): 116-122, 1976
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event, it is commonly described as coming on all at once,
that is , without a march.
The typical history for a TIA in the vertebrobasilar
arterial system is . .
I. Motor defect (weakness, clumsiness, or paralysis
of any combination of extremities up to quadriplegia,
sometimes changing from one side to another in different attacks).
2. Sensory defect (numbness, including loss of sensation or paresthesias in any combination of extremities
including all four or involving both sides of the face or
mouth. This is frequently bilateral trouble or the distribution may change from side to side in different attacks).
3. Loss of vision, complete or partial in both homonymous fields (bilateral homonymous hemianopia).
4. Homonymoµs hemianopia.
5. Ataxia, imbalance, unsteadiness, or dysequilibrium
not associated wit)l vertigo.
6. Either vertigo (with or without nausea and vomiting), diplopia, dysphagia , or dysarthria is not to be considered as a TIA when any of these symptoms occurs
alone, but in combination with one another or with any
of the above (numbers I, 2, 3 and 4) the attacks should be
considered a TIA.
7. Combinations of the above.
These clinical phenomena generally represent a decrease or absence of function. At times, the motor, sensory , or visual defect constituting the content of a vertebrobasilar attack will be unilateral. It becomes difficult
in such instances to make a distinction between whether
the locus of ischemia is in the carotid arterial system or in
the vertebrobasilar arterial system . In the list above,
"drop attacks" is omitted. Fainting (syncope) is frequently confused with a " drop attack ," so the latter
should be included in the vertebrobasilar profile only
when the patient's description of the "drop attack " is
abso lutely clear. The variety of manifestations included
in the vertebrobasilar profile makes the potential pattern of symptoms considerably more variable and complex than that in the carotid system.
The diagnosis of TIA rests on the history of the attacks; the skill with which the history is taken and the
interpretation of the history , except for those relatively
few instances where the physician is with the patient at
the time of the attack. The criteria for making the diagnosis will vary depending on whether an individual
physician is working with an individual patient or
whether the purpose is the screening of a population for
TIAs. A problem is created , as in much of medical diagnosis , because of the relative weight or significance of
some historical phoriomena compared to other phenomena. The symptom "numbness" (mentioned above) is
an example. If the question is, "Have you ever had a
numb hand 9 , " the answer from most adults will be "yes."
This question is almost completely non-selective (nondiagnostic) and must be followed by a series of questions
to establish the meaning and significance of the "numbness. " In contrast , another phenomenon , when present ,
is simple and relatively much more significant than
"numbness;" i.e., "Have you ever had painless blindness
in one eye which came on very quickly (seconds) and

lasted only a few minutes (5 to 20)?" is a question
which , if answered "yes," is reasonably specific. Another
similar but less specific question is " Have you ever had
the sudden onset of a 5 to 20-minute duration attack of
severe weakness of one side of the body (arm and leg)?"
Another is "Have you ever suddenly lost the ability to
speak (5 to 20 minutes' duration) or to understand the
speech of others?" These questions illustrate the importance of understanding that different questions may have
relatively different cqmplexity and importance .
The matter of relative significance of different symtoms is important in the vertebrobasilar system as it is in
the carotid system. For instance, if one asks the question ,
"Have you ever had any dizziness" ," almost all adults
will answer "yes." This question is almost completely
non-selective (non-diagnostic) and if answered affirmatively must be followed by a series of direct and branching questions to e?tablish the meaning and signific;mce
of the original phenomenon-"dizziness." A diagnosis of
a TIA in the vert~brobasilar system should not be made
on the basis of a history of a few minµtes of vertigo as the
only symptom. This is emphasized since vertigo is the
most common symptom in the vertebrobasilar system ;
however, a diagnosis of vertebrobasilar TIA is made only
when there is concurrently with vertigo (dizziness) an additional symptom or symptoms.
In some instances, patients with carotid system
TIAs may have physical signs of appropriate arterial
disease. These include diminished pulsation in the carotid
artery, a bruit over the carotid artery or eye, emboli in
the retinal vessels, or other signs of ischemic retinopathy
and relative hypotension in the retinal artery as measured
with the ophthalmodynamometer. These are only signs
of arterial disease and may be present in the absence of
a history of TIAs. In certain instances , bruits signifying
compromise of flow in the innominate artery, either
subclavian artery, or at the origin of ei ther vertebral
artery may be present ; however, the a bsence or presence
of such sounds does not weigh heavily in the diagnosis of
vertebrobasilar TIA since it is again emphasized that
the diagnosis is dependent upon the history of the attack , not upqn morphological evidence of change in
patterns of blood flow .
Certain symptoms may appear in a TIA in either
arterial system . The most important of these are:
I. Dysarthri~ , if it occurs alone, and
2. Homonymous hemianopia , if it occurs alone.
The occurrence of certain symptoms in solitary
fashion constitutes an attack which is an "uncertain
TIA. " An attack which consists solely of eac h of the following symptoms should be categorized as an uncertain
TIA:
I . Vertigo a lone
2. Dysarthria alone
3. Dysphagia alone
4. Diplopia alone
For the sake Qf clarity, the following symptoms ,
transient or prolonged, are not to be included as TIA:
I. Unconsciousness including syncope
2. Tonic and / or clonic activity
3. March of a sensory defect
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4. Vertigo alone
5. D ysphagia alone
6. D ysarthria alone
7. Incontinence of bowel or bladder
8. Dizziness or wooziness a lone
9. Loss of visio n associated wi th alteration of consciousness
IO. Focal symptom s associated with migraine
11. Scintillating scotomata
12. Confusion alone
13. Amnesia alone
The differential diagnosis of TI As includes "hemiplegic" migraine, focal convulsive events (often due to
neoplasm and producing either sensory or motor
phenomena), Meniere' s disorder, sensory phenomena
associated with hyperventilation, and finally some unknown mechanism. The differentiation of "hemiplegic"
migraine is a semantic and practical problem. In those instances where the aura of migraine is associated with a
definitely focal neurological event, the latter may well
be the result of transient focal cerebral ischemia but the
implications are different than the usual TIA. To establish a diagnosis of the migraine association, there
is ordi narily a positive family history, characteristic unilateral headache with nausea and sometimes vomiting,
and onset of the a ttacks several deca des ahe~d of the age
at which T!As commonly begin. Very careful historytaking ordinarily delineates the transient focal events
associated with brain neoplasm from T!As and this is
also true of the other items in the differential diagnosis.'

It is necessary to understand the pathogenesis of
the attacks to treat them properly. Strokes occur in
people who have atherosclerosis; common sites are in
the cervical arteries and in the circle of Willis and its
main branches. Strokes do not occur in patients free
of atherosclerosis unless there is a distal occlusion by
an embolus from the heart or other site. Cerebral
infarcts are statistically associated with ather()sclerosis. How does a static atherosclerotic lesion
in the neck produce the sudden onset, in a matter of
seconds, of a hemiparesis which lasts for five minutes
and disappears leaving the person normal? How often does cerebral atherosclerosis occur without causing symptoms? In 100 consecutive autopsies of
patients 50 years of age or older, the arch of the
aorta, all cervical vessels, vessels at the base of the
brain , and the brain were studied. Under the term
"stenosis," only a lumen narrowed 50% or more was
counted. There were 77 cervical stenoses in 28
patients. Of these 28 people, 18 had never had any
sy mptoms of nervous system trouble of any kind .
There were 15 cervical occlusions in 12 people. Six of
these 12 had never had any symptoms of nervo us
system trouble. There were 40 people (40%) of
the I 00 who had cervical atherosclerosis, not count-

ing intracranial lesions . Sixty percent of these patients were without any symptoms of nervous system trouble. This same observation has been made
concerning coronary atherosclerosis. Many people
with coronary atherosclerosis have neither angina
nor a myocardial infarction . It is apparent that some
factor, in addition to atherosclerosis, has to be present
to produce the sudden onset and short duration of
the attacks . In 1955, I postulated that atherosclerosis plus one or more of the following could cause
an attack: tra,nsient systemic hypotension, polycythemia, kinking or external compression, shunting,
transient hypoglycemia, vasospasm , severe anemia,
thrombosis or embolism or both. The transient systemic hypotension theory was in vogue over a decade
ago. The notion was that if there were distal stenosis
of an artery and the perfusion pressure dropped ,
there would be a disproportionate decrease in perfusion distal to the stenosis, thereby causing ischemia
for the duration of that decreased perfusion pressure,
and ischemia in the territory supplied by that vessel.
The physician should search for cardiac causes of
transient systemic hypotension even though this is an
uncommon cause of TIA . At the Mayo Clinic, only
1.4% of 290 consecutive patients being implanted
with cardiac pace makers had had focal transient neurological phenomena. In most instances there were
episodes of diffuse cerebral ischemia (syncope). Polycythemia is found in I% or 2% of our TIA patients,
whether vertebro-basilar or carotid. Polycythemia
should be appropriately studied and treated . Reversal
of flow in a vertebral artery because of occlusion or
stenosis of a subclavian artery has been called "subclavian steal." It can be diag nosed in the office as
there is a decrease in brachial blood pressure on the
side involved, a radial pulse lag, and a decrease in the
palpable pulse pressure on that side. The symptom
complex associated with this, certainly in our institution, has never been defined and operations for this
defect are seldom performed.
The items of greatest importa nce in the pathogenesis of TIA appear to be thrombosis and embolism . Cholesterol and fibrin-platelet emboli have been
observed in the retina; streamlining of flow explains
the similarities between the neurological content of a
patient's attacks while fragmentation of emboli or
lysis of thrombosis is a plausible explanation for the
short duration of episodes. The appearance of cholesterol emboli in the retina means that there is an
ulcerated carotid lesion on that side.
The natural hi story of TIA has received consid-
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erable study. Are TIAs warning events? Twelve reports are summarized in the following table (Table
I ).
The one study with a result different from the
others is Marshall's .9 A few months later, Marshall1 3
published an entirely different result ; 43 % of TIA
patients had cerebral infarction when followed for
60 months. In Marshall's first report it appears that
many of the patients had a complaint of occasional
dizziness and were not having focal cerebral transient
ischemic attacks. In the study by Pearce et al,5 the
duration of follow-up was only 10.6 months which
is too short a time to discover the true natural history
of TIA.
One is often asked about the indications for cranial arteriography. These are:
I. Differential diagnosis of the brain pathology.
Even with careful attention to all the items listed
under history, general examination , neurological examination, neurovascular examination, and additional tests, there still remain about 5% of patients
whose diagnosis is uncertain. Computerized tomography (EMI, ACTA , DELTA scanners, and others)
is revolutionizing the differential diagnosis of intracranial lesions. In a few instances , cervical-cerebral angiography is the best method for distinguishing between vascular occlusive disease, an
intracerebral expanding mass such as hemorrhage,
abscess or brain tumor, cerebral infarction, and subdural hematoma , as well as demonstrating aneurysms
and arteriovenous malformations.

2. Transient focal ischemic attacks, particu larly
in the carotid system. Cervical-cerebral angiography
should be performed if one or more of these conditions is evident: amaurosis fugax, bruit over the beginning of the internal carotid artery, retinal emboli,
unilateral decrease in retinal artery pressure, or ischemic retinopathy . If none of these is present, the
likelihood of finding a lesion accessib le to the surgeon
is small.
3. Selected instances of vertebra-basilar TIAs.
It may be difficult to make a clinical distinction between the carotid and the vertebra-basilar system. If
the TIAs are characteristic of those coming from the
vertebra-basilar system, there is little need for extensive angiography .
4 . Early progressing stroke or frequent TIAs in
the carotid system with evidence of amaurosis, an
appropriate bruit, retinal emboli, or other conditions.
5. Many patients with subarachnoid hemorrhage and some patients with intracerebral hemorrhage.
A less certain indication for cranial arteriography is a loud, long systolic or systolic-diastolic
internal carotid artery bruit in patients scheduled for
major general surgery. If there is prolonged hypoten sion or very severe blood loss, the carotid stenosis
may decrease blood supply to a focal region of the
brain to a critical level of ischemia. Recent observations suggest that such patients do not have an increased risk of stroke; therefore, arteriography is not
necessary.

Table I
Twelve Reports Summarizing Natural History of TIAs as Warning Events

STUDY
Sieker! et al'
Cooperative'
Fisher'
Pearce et a I'
Baker et al'
Baker et al'
Friedman et al'
Marshall'
Ziegler and Hassa nein"
Goldner* et al"
Whisnant et al 12
Marshall 13

NU MBE R OF
PATIENTS

FOLLOW- UP
(Mos.)

160
20
23
20
30
79
23
61
135
140
Ill
198
158

60
20
10.6
40.6
41
27.4
45
36
180 av •1
av?
60
60

NORMAL
83 (52%)

11 (55 %)

54 (89%)

CEREBRAL INFA RCT
TOTAL
LETH AL

CER EBRA!.
HEMORRHAGE

0

7(4%)
0
0

0

I (2%) SAH

51 (32%)
5 (25%)
8(34%)
2(10%)
7 (23%)
17 (22%)
8 (35 %)
1 (2%)
22(16%)

18(11 %)
1 (5%)

43 (38%)
62 (32%)
68 (43%)

27 (24%)

I (2%)

5 (3.7%)

*Goldner, Whisnant and Taylor reported concerning 140 TIA patients followed for 15 years. The table gives occurrence of stroke
in 111 patients.
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Recalling the thrombosis-embolism mechanism ,
it is apparent that there are several ways to treat
TIAs; one of these is the administration of an oral
anticoagulant. Table 2 shows the data in six reports
in which a direct attempt has been made to compare
untreated patients suffering from transient ischemic
attacks with those receiving anticoagulant drugs.
Anticoagulants should not be used if: 1) the
physician is unfamiliar with the drugs, 2) the patient
is not fully cooperative, or 3) laboratory results are of
uncertain quality. The actual number of patients in
five of the studies in Table 2 is so small as to make
comparison between the treated and untreated
groups invalid. Nevertheless, the percentage of individuals with cerebral infarction was similar in
all of the treated groups of each study. The effectiveness of concurrent treatment of arterial hypertension,
in decreasing the frequency of intracerebral hemorrhage, cannot be assessed in these studies; it seems
reason a ble that the dange r may be less now that
antihypertensive therapy is better developed. It is
apparent that anticoagulant therapy decreases the
risk of cerebral infarction in patients with transient
ischemic attacks. However, other types of treatment
should be considered including thromboendarterectomy an d the administration of antiplatelet agglutinating agents.

Although thousands of operation s on the carotid
artery have been performed since the report by Eastcott, Pickering and Rob 14 in 1954, knowledge concerning the effects of surgery to prevent subsequent
cerebra l infarction in patients with TIA is still limited . In the Joint Study of Extracranial Arteria l Occlusion V, 15 the collaborating investigators reported
that 316 patients had transient ischemic attacks; 169
received surgical treatment and 14 7 received medical
treatment. The follow-up period averaged 42 months.
In the surgically treated gro up, 15% of the patients
suffered cerebral in farction (including postoperative
comp lications) while 14% of the medically trea ted
subjects had cerebral infarction. The best results were
noted in a subgroup of 94 patients having transient
ischemic attacks and unilateral carotid stenosis; 45
underwent surgery and 49 were treated medically. Six
percent of the surgica lly treated patients had cerebral
infarction during the total course of the study compared with 12% of the medically treated group. Ba ue r
et a l, 16 a lso reporting for the Joint Study of Extracranial Arterial Occlusion, noticed statistically significant differences in the cumulative survival rates at 42
months and reported that:
( I) surgical treatment appeared more beneficial for
unilateral carot id stenosis in patients with transient
ischemic attacks or a mild to moderate neurological

TABLE 2
Six Studies Comparing Untreated TIA Patients with Those Receiving Anticoagulant Therapy
STUDY
Siekert el al'
Control
Treated
Cooperative Study'
Control
Treated
Fisher'
Control
Treated
Pearce et a l'
Co ntrol
Treated
Baker et al'
Control
Treated
Friedman et al'
Control
Treated

NUMBER OF
PATI ENTS

FOLLOW-UP
(Mos.)

NORMAL

160
175

60
60

83 (52%)
131 (75%)

20
24

CEREBRAL INFA RCT
LETHAL
TOTAL

CE REBRAi.
H EMO RRllAGF

51 (32%)
7(4%)

18( 11 %)
3(2%)

7 (4%)
13 (7%)

20
18

5 (25%)
I (4%)

I (5%)
0

0
2 (8%)

23
29

30

8(34%)
I (3%)

0
0

0
0

20
17

II.I

30
30

40.6
37.9

7* (23%)
2

23
21

27.4
27.4

8•
0

10.6

11 (55%)
7 (4 1%)

2( 10%)
I (5%)

*Three treated patients randomly chosen had CY A after A/ C stopped.
1 One cerebral hemorrhage in treated group but while off anticoagulant.
' One patient had been on A/ C, but A / C was discontinued before the cerebral infarctio n.

0'
0
0

I (4%) SAH
0
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deficit, (2) nonsurgical treatment produced better results
for unilateral carotid stenosis in patients with a moderate
to severe neurological deficit, (3) nonsurgical treatment
appea red more beneficial for combined unilateral
carot id a rtery stenosis and con tra latera l carotid artery
occlusion o f patien ts who had a moderate to severe
neurological deficit, and (4) nonsurgical treatment appea red more beneficial for patients with comp leted
strokes who had a marked and persistent neurological
deficit.

It is apparent from the m a ny reports in the litera ture tha t physicians clinically active in the cerebrovascular field are modera tely to g rea tly e nthusiastic
about surgica l treatment for carotid system TIA
when a n appropriate carotid lesion is di scovered. U nfortunately, no long-term follow-up of a precisely
studied group o f surgicall y treated carotid TIA
p a tients is available, but it seems likely that results
have improved since the report by the Joint Study of
Extracra nia l A rteri a l Occlusion .
In the last decade, aspirin, dipy ridam ole (Persantine®) and sulfi npyrazo ne (Anturane®) have been
investigated in the la boratory and in some huma n
clinical settings because of their effect on blood platelet aggregability or ad hesiveness o r both. A direct
relationship between these characteristics of platelets
a nd the pathogenesis of transient ischemic attac ks
h as not yet been firmly established . Dyken et al1 7 described 26 p atients, in a retrospective study, of whom
15 were treated with aspirin (300 mg b.i .d .) and 11
we re not. No difference was noted in the incidence of
cerebral infarction or death in the two groups, but
on ly two ( 13%) of those receiving aspirin had an additional TIA while nine (82%) of those receiving no
aspirin had subsequent TIA . The author stressed that
this study did not prove the effecti veness of aspirin ,
but that it pointed to the need for a prospective investigation of the subject.
Two cooperative studies of platelet aggregating
agents' effect o n transient ischemic attacks are underway, one in Canad a and o ne in the United States.
Formal comp re he nsive reports from these studies a re
not yet available. A tthe Tenth Princeton Conference
on Cerebral Vascular Disease in 1976, Fields 18 gave a
brief overview of some of the experience in the
United States Cooperati ve Study of aspirin for the
treatm e nt of transient foca l cerebra l ischemic attacks.
H e reported that in patients hav ing one attack, there
was no difference between treated and untreated
patients, but that in patients h aving multiple TIAs,
those receiving aspirin appeared to have a better "result. " This Cooperative Study has been discontinued.
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Barnett'" (Canadian Cooperati ve Study ) was asked
about the res ults of his investigation which in volved
comparisons between several treatments (aspirin, sulfinpyrazone, and other drugs). He commented that
the stat istics to date had been ca refully reviewed and
that the results appeared to be inconclusive. There
was no reason to stop the in vestigatio n and every
reaso n to co ntinue it. At this time, the pressing questions concerning t he effectiveness of these agents rema in unan swered .
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Recent Techniques in Cerebrospinal Fluid
Examination
VINCENT P. CALABRESE, M .D .
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The existence of the cerebrospinal fluid (CSF)
has been known since ancient times, but it was Cotugno who first described it in some detail in 1764. 1
Quoting from his treatise, "In these experiments
which I made on the bodies of nearly twenty adults,
and which I repeated at different times , I could draw
off freely from the hollow of the spine, four, or even
sometimes five ounces of water: I commonly found it
very clear in such su bjects, though it sometimes inclined a little to a yellow color: but in fetus' strangled
in difficult labor, little as it was, I observed it to be
always red and opaque." 2 He also felt that the CSF
was secreted by the arterial system, circulated in the
subarachnoid space and was reabsorbed by the
venous system. 2 Matters remained in that state until
1891 when Quincke described a refinement in lumbar
puncture using a needle with a pointed stilette in it. 3
The first extensive treatise on CSF composition was
written by Mestrezat in 1912 . 1 Since then there has
been very slow progress in the evaluation and interpretation of CSF even though there have been tremendous strides in the evaluation of other body
ft uids, particularly blood .
One of the reasons for this is a fear of lumbar
puncture, a fear which is usually unwarranted. Unfortunately, this attitude permeates the medical profession almost as much as it does the lay public.
Tests such as cell counts, glucose, protein, and
semiquantitative tests for globulins such as the colloidal gold test were products of the first part of this
Correspondence and reprint requests to Dr. Vincent P. Calabrese, Department of Neurology , Box 698 , Medical College of
Virginia, Richmond , Virginia 23298.
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century. As new developments occurred in blood
analysis these were applied to the CSF . These studies
did not lead to any advances in the clinical chemistry
of CSF, though they certainly had their place in
furthering our understanding of brain chemistry and
function .
The biggest advance in clinical CSF chemistry in
the past decade has been the emergence of an abbreviated CSF immunology. This followed the development and refinement of agar electrophoresis and imm unoprecipitation techniques.
The scope of this paper will include discussion of
these advances and some promising studies of CSF
enzymes in differential diagnosis as well as comment
on a recurrent problem , that of the interpretation of
bloody or xanthochromic CSF.
Blood in the CSF. Probably one of the most
frequently encountered problems is the bloody CSF.
Is it a subarachnoid hemorrhage or is it a traumatic
tap?
One of the best tests and the one most commonly
used is to do a cell count in the first tube and another
in a subsequent tube, usually the third . This should
be done even if the fluid looks grossly clear since
about 500 cells must be present before the fluid becomes hazy .4 •5 A significant change in the red blood
cell (RBC) count of the fluid indicates a traumatic tap
since the blood from a subarachnoid hemorrhage
should be homogeneous by the time it reaches the
lumbar sac. I say a "change" in the RBC, not just a
decrease, since a marked increase would also indicate
a traumatic tap . One should also closely observe the
fluid as it comes out of the needle . Gross blood can
sometimes be seen streaming in the fluid. One may
123
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also see nonhomogeneous mixing in the ft uid as it
drops into the tube. In addition, a very bloody traumatic tap (greater than 200,000 RBC/ mm 3 ) will clot
on standing; this will not occur with subarachnoid
bleeding. Microscopic examination of the red cells is
of little value since crenation may occur with both
subarachnoid bleeding and a traumatic tap.
The next step if the fluid is bloody or colored
should be to centrifuge the fluid and determine the
color of the supernatant. One often hears the remark
that the fluid was xanthochromic, yet the fluid was
not centrifuged. Xanthochromia should refer to a
yellow color of the supernatant and should never be
used in reference to unspun CSF. This coloration is
usually due to either oxyhemoglobin, methemoglobin,
or bilirubin. Very rarely it may be due to other pigments such as carotene. 6
The sequence of events appears to be: hemoglobin is released from the red cells in the subarachnoid
space. This appears as oxyhemoglobin which in low
concentrations has an orange-red appearance. Depending on the amount of bleeding, one begins to see
a change in the coloration of the fluid to yellow
within a few hours to a day. This is due to the heme
being metabolized to bilirubin. In the case of a subdural or an intercerebral hem atoma the fluid may
take on a brownish-yellow appearance due to the
presence of methemoglobin.
The supernatant fluid in a traumatic tap can give
one of two results. It is usually clear and colorless
since the red cells have not had time to break down . If
the RBC count is high, however, (> 12,000/ mm 3 ),
some of the hemoglobin lea king out may be visible
immediately.5
True subarachnoid bleeding will give different
results depending on the time elapsed following the
bleed . One should keep in mind that it may take a
half hour for blood to reach the lumbar sac from the
cortex. The CSF may be indistinguishable from a
traumatic tap very shortly after the hemorrhage. In
his classic text on subarachnoid hemorrhage, Walton
observed xanthochromia in 7% of patients within 2 to
4 hours, but by 4 to 6 hours, 64% had it, and by 12 to
24 hours, 100% had it. 7
There have been periodic attempts at using spectrophotometry as an aid in evaluating CSF pigments.
The three major pigments have rather characteristic
absorption patterns. Kronholm and Lintrup did a
study on 1,250 CSF samples and were able to develop
a set of formulae for determining the concentrations
of hemoglobin, methemoglobin, and bilirubin. Their

results showed that they could distinguish between
intercerebral hem atomas, subdural hematomas, and
subarachnoid hemorrhage (Table 1; Fig 1). 8
More recently, Kjellin and his group have expanded on this theme of CSF spectroscopy .9 ·' 0 Besides the disorders noted above, they have been able
to correlate various CSF patterns with hemorrhagic
infarctions, nonhemorrhagic infarctions, and emboli ,
as well as hem a tom as and subarachnoid hemorrhage.
In the past they have had to rely on clinical and
occasional autopsy conformation. When this was
available there was good correlation (Table 2 ).
I do not advocate that these procedures be used
in place of others for evaluation of bloody CSF, but
as adjuncts which may be invaluable in deciding if a
!um bar puncture was traumatic or not.
CSF Proteins and Immunoglobulins. There is considerable evidence that under normal circumstances
the proteins of the CSF are derived from the serum ."
The most notable exception is the so-called (tau)
protein seen in electrophoresis which is probably serum transferrin which has lost two sialic acid residues
(Fig 2). Normally, the CSF proteins are made up of
albumin, (3 globulin and 'Y globulin in the fractions
0.58, 0.20, and 0.10 respectively. These get into the
CSF by secretion from brain tissue as well as from the
choroid plexus. Efflux of protein is presumably
through bulk flow , through the arachnoid granules.
Increases in protein , especially albumin, can come
from: 1) hemorrhage into the CSF, 2) breakdown in
the blood-brain barrier, 3) elevated serum protein, 4)
lesions of the choroid plexus or 5) blockage of CSF
flow, for example, spinal block , and 6) an efflux of
soluble proteins into the CSF with damage to brain
tissue.
CSF 'Y globulin or IgG also comes from the
serum in normal persons. In conditions where there is
Table I
CSF Pigments in Xanthochromic CSF
lnte rcerebral hematoma

Bilirubin > Hemoglobin
Methemoglobi n > 25% total Hb

Subdural

Same as above, but metheme
m ay be very high

Subarachnoid

He moglobin > Bilirub in
Methemog lo bin < 25%

Traumatic

Same as subarachnoid though
Bilirubin should be negligible
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Fig I-Absorption pattern of CSF. A is from a patient who did not have active CNS disease. Bis from a patient who presented with a
history of confusion and a bloody CSF. The absence of a hemoglobin peak indicates blood was from a tra umatic tap, but bilirubin indicates
an older subarachnoid hemorrhage. C is from a patient three weeks after an intercerebral hemorrhage. The hemoglobin peak is over 50%
metheme. D is hemolyzed blood.
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Table 2
Spectrophotometric Evaluation of CSF in Vascular Disease
Pattern (% of cases)*
Hemorrhagic infarction
or
Hematoma

Infarction

Verified Disease

24
46
8

71
9

Infarction
Cerebral Hemorrhage
Aneurysm
Trauma (not subdural)

Mixed

Hemorrhage

8
8
18

83

27

82

*A small number could not be interpreted, so figures do not add up to !00%.

an increased serum 'Y globulin or IgG, this will be
reflected in the globulin composition of the CSF. In
addition, if there is a breakdown in the blood-brain
barrier, one may see an increase in the 'Y or lgG
fraction simply because it makes up a higher proportion of the total protein in serum than it does in CSF.
There are times, though, when it appears that the
increased immune globulins are coming from the
brain itself. This was shown some years ago by Frick
and Scheid-Seydel who used tagged lgG. 11 In multiple sclerosis (MS) patients they showed that a large
portion of the lgG was coming from somewhere
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Fig 2-Agar gel electrophoresis of concentrated CSF and unconcentrated serum. Note presence of a prealbumin a nd a tau band in
CSF which is not present in serum. Also note very broad gamma
band.

other than serum. At present it is thought that it is
coming from immune competent cells situated in the
periphery of MS plaques. 12 Other conditions which
are felt to reflect central nervous system (CNS) lgG
production with a raised CSF IgG are neurosyphilis
and subacute sclerosing panencephalitis. Disorders
such as meningitis or encephalitis may show increased IgG either from a breakdown in the bloodbrain barrier or CNS production.
In 1964, Lowenthal applied agar electrophoresis
to CSF and was able to confirm this increase in immune globulins (See Fig 2; Fig 3). 13 Interestingly, conditions which have CNS immune globulin production
usually show discrete banding of the 'Y fraction while
those conditions in which the immune globulins originate in serum show a diffuse 'Y band . The next advance after agar electrophoresis was the development
of immunoprecipitation methods, either electroimmunodiffusion or radial immunodiffusion
where antibody to the immune globulins is added to
the agar. The distance of the resultant precipitate
from the origin is proportional to the immune globulin concentration. The advantage over electrophoresis is that only a few microliters of CSF are
needed, and the subfractions of the immunoglobulins
can be measured . The disadvantage is that only one
protein fraction can be measured at a time.
Interestingly, the results by the different methods are remarkably similar. 13 - 20 In MS some 75%
to 85% of the patients show an abnormal 'Y or IgG
level at some time in their disease. There is no relationship, however, to the stage of the disease or to
the prognosis. Its value is therefore purely diagnostic.
Inflammatory diseases such as meningitis and encephalitis show an increased level in some 35% to
40%, the lowest level being in viral meningitis. Guillain-Barre syndrome shows an increase in 30% to
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50%. Agar electrophoresis shows that this is a serum
pattern . In other diseases s uch as degenerative disease, tumors, and vascular disease, the percentage
with increased 'Y or IgG levels is quite low, though in
these conditions the literature does vary a great deal
a nd probably reflects variations in the integrity of the
blood-brain barrier (Table 3 ).
CSF Enzymes. The meas urement of CSF enzyme
levels has no t yielded the kind of information which
was hoped for. The ones measured most common ly,
lactic dehydrogenase (LDH) and glu tamic-oxalacetic
Table 3
Conditions Giving Elevated CSF Gamma Globulin

Systemic Conditi o ns with
Co nditions with I 0 Increase
Increased CSF Immune G lobulins in CSF Immune G Jobulins
Multiple Sclerosis
CNS Lues
SSPE

Vascu l itis.~----?Vascul i t i s*

In fection----~I nfection *
Sarco idosis---~S a rcoidos i s*

* In these three it is uncertain if the origin of the gamma
globulin is serum or CNS or both.
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Fig 4-CSF LDH isoenzymes measured by aga r gel electrophoresis. Normal LDH 2+ 3 = 0.40 and LDH I = 0.55. The
LDH 2+ 3 curve foll ows the tota l LDH pattern whi le the LDH I
actually showed a slight increase at two days when the absolute
amount was calculated.

transaminase (GOT), ap pea r to be elevated whenever
there is significant disruptio n of brain tissues a nd do
not seem to be specific for a given disease. The LDH
is a lso increased when there is an increase in CSF
polymorp honuclear cells. This relation to tissue destruction is shown by the results from a patient with
recurrent strokes. Using LDH isoenzymes, it is of
interest to note the transient shift to the more anaerobic forms of LDH during the acute phase (Fig 4).
CSF LDH has been noted to be elevated in
meningitis of bacterial origin, but rarely in viral. 21 - 23
T his elevation has been used to try and differentiate
partially treated bacterial from viral meningitis.2 4 For
technical reasons the results were not really conclusive, but it d id ind icate a differentiatio n could be
made by an elevated level in bacterial d isease.
More impressive was a study on CSF lactate
before, during, and a fter treatment. 25 Bacterial disease showed an elevated lactate level un til after full
treatment while aseptic meningitis was the same as
the controls. CSF pH showed the inverse pattern as
wou ld be expected .
While further studies wi ll be necessary to confirm these results, the outlook for a test to distinguish
partially treated bacterial disease from a viral meningitis looks promising.
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Table I is adapted from Kronholm and Lintrup, Acta Psychiat
Neural Scand (35:314-329, 1960).

13. LOWENTHAL A: Agar gel electrophoresis in neurology. Elsevier,
Amsterdam , 1964.

Table 2 is adapted from Kjellin and Soderstrom, J Neural Sci (23:
359-369, 1974 ).

14. SCHNECK SA, CLAMAN H: CSF immunoglobulins in multiple
sclerosis and other neurologic diseases. Measurement by electroimmunodiffusion. Arch Neurol 20:132-139, 1969.
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